Overview

Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

This study is designed for single-center, randomized, open label, standard therapy controlled. 60 COVID-19 subjects with a treatment period of 10 days and follow-up until 28 days after enrollment.

Phase:

N/A

Details

Lead Sponsor:

Shanghai Public Health Clinical Center

Collaborator:

Kunming Pharmaceuticals, Inc.

Treatments:

Colchicine